TOPICS

Tag: minocycline

Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

J Clin Aesthet Dermatol. 2021;14(3):E53–E57.  by Terry M. Jones, MD, and Iain Stuart, PhD Dr. Jones is with J&S Studies Inc., in College Station, Texas. Dr. Stuart is with VYNE Therapeutics Inc., in Bridgewater, New Jersey.  FUNDING: This study was sponsored by Foamix Pharmaceuticals Ltd., a wholly owned subsidiary of VYNE Therapeutics Inc. DISCLOSURES: Dr.

CONTINUE READING »

A Case of Minocycline-induced Linear Morphea Reactivation

J Clin Aesthet Dermatol. 2021;14(2):44–45. by Cory Pettit, MD, and Joy Mosser-Goldfarb, MD Drs. Pettit and Mosser-Goldfarb are with the Division of Dermatology, Department of Internal Medicine, The Ohio State University Wexner Medical Center in Columbus, Ohio. FUNDING: No funding was provided for this article. DISCLOSURES: The authors report no conflicts of interest relevant to

CONTINUE READING »

Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX103 1.5% Minocycline Topical Foam for the Treatment of Moderate-to-Severe Papulopustular Rosacea

J Clin Aesthet Dermatol. 2020;13(11):44–49 by Linda Stein Gold, MD; James Q. Del Rosso, DO; Leon Kircik, MD; Neal D. Bhatia, MD; Deirdre Hooper, MD; Walter Nahm, MD, PhD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Del Rosso is the Research Director at JDR

CONTINUE READING »

Oral Antibiotic Treatment Options for Acne Vulgaris

J Clin Aesthet Dermatol. 2020;13(9):26–32 by Hilary Baldwin, MD Dr. Baldwin is the Medical Director of the Acne Treatment and Research Center in Brooklyn, New York and is with Rutgers Robert Wood Johnson Medical Center in New Brunswick, New Jersey. ABSTRACT: Acne vulgaris is the most common dermatological disease in the United States, affecting up

CONTINUE READING »

Open-label Extension Study Evaluating Long-term Safety and Efficacy of FMX101 4% Minocycline Foam for Moderate-to-Severe Acne Vulgaris

J Clin Aesthet Dermatol. 2019;12(10):16–23 by Linda Stein Gold, MD; Sunil Dhawan, MD; Jonathan Weiss, MD; Zoe Diana Draelos, MD; Herman Ellman, MD; and Iain Stuart, PhD Dr. Stein Gold is with the Henry Ford Health System in Detroit, Michigan. Dr. Dhawan is with the Center for Dermatology Clinical Research, Inc., in Fremont, California. Dr. Weiss

CONTINUE READING »